

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

MALLINCKRODT PLC.,

Reorganized Debtor.¹

Chapter 11

Case No. 20-12522 (BLS)

**NOTICE OF FILING OF PERIODIC REPORT OF THE OPIOID MASTER
DISBURSEMENT TRUST II**

TO OPIOID CREDITOR TRUSTEES, THE FUTURE CLAIMANTS' REPRESENTATIVE,
AND ALL OTHER INTERESTED PARTIES:

PLEASE TAKE NOTICE that, in accordance with Section 3.02(b) of the Opioid Master Disbursement Trust II Trust Agreement dated as of June 16, 2022 (the "Trust Agreement"), Jennifer E. Peacock, Michael Atkinson, and Anne Ferazzi, in their capacities as the Opioid Master Disbursement Trust II Trustees (the "Trustees"), have filed a periodic report (the "Periodic Report"), attached hereto as **Exhibit 1**. As further required by Section 3.02(c) of the Trust Agreement, the Periodic Report will be posted on the Opioid Master Disbursement Trust II website at www.opioidmasterdisbursementtrust.com/Mallinckrodt.

¹ The Reorganized Debtor in this chapter 11 case is Mallinckrodt plc ("**Mallinckrodt**"). On May 3, 2023, the Court entered an order closing the chapter 11 cases of the Reorganized Debtor's debtor-affiliates (together with Mallinckrodt, "**Debtors**"). A complete list of the Debtors in these Chapter 11 cases may be obtained on the website of the Reorganized Debtor's claims and noticing agent at <http://restructuring.ra.kroll.com/Mallinckrodt>. The Reorganized Debtor's mailing address is 675 McDonnell Blvd., Hazelwood, Missouri 63042.

Dated: February 20, 2025

Respectfully submitted,

COLE SCHOTZ P.C.

/s/ Justin R. Alberto

Justin R. Alberto (No. 5126)
Patrick J. Reilley (No. 4451)
500 Delaware Avenue, Suite 1410
Wilmington, DE 19801
Telephone: (302) 652-3131
Facsimile: (302) 652-3117
jalberto@coleschotz.com
preilley@coleschotz.com

Anthony De Leo, Esq.
Julie A. Aberasturi, Esq.
1325 Avenue of the Americas, 19th Floor
New York, NY 10019
Telephone: (212) 752-8000
Facsimile: (212) 752-8393
adeleo@coleschotz.com
jaberasturi@coleschotz.com

-and-

BROWN RUDNICK LLP

David J. Molton, Esq.
Gerard T. Cicero, Esq.
Seven Times Square
New York, NY 10036
Telephone: (212) 209-4800
Facsimile: (212) 209-4801
dmolton@brownrudnick.com
gcicero@brownrudnick.com

-and-

Jane W. Motter, Esq.
One Financial Center
Boston, MA 02110
Telephone: (617) 856-8200
Facsimile: (617) 856-8201
jmotter@brownrudnick.com

*Co-Counsel to the Opioid Master Disbursement
Trust II*

EXHIBIT 1

Periodic Report Ending January 31, 2025

Opioid Master Disbursement Trust II
Table of Contents
For the Reporting Period Ending January 31, 2025

Section	Page Number
<i>Introduction</i>	2
<i>Reporting Period Activity</i>	2
<i>Financial Update</i>	3
<i>Legal Matters Update</i>	3
<i>Exhibit A</i>	8
<i>Appendix</i>	10
<i>Appendix 1: Trust Financial Summary</i>	11
<i>Appendix 2: Trust Budget</i>	13

Opioid Master Disbursement Trust II

Report for Period October 1, 2024, through January 31, 2025

Introduction

Pursuant to Section 3.02 of the MDT II Trust Agreement, the Opioid Master Disbursement Trust II (“MDT II” or “the Trust”) is obligated to report to each of the Opioid Creditor Trusts and the Future Claimants’ Representative,¹ at least every four months, on topics including the Trust’s:

- Assets;
- Expenditures;
- Distributions;
- Forward-looking projections; and
- Litigation proceedings.

The following report, for the period beginning October 1, 2024, and ending January 31, 2025 (the “Period”),² fulfills such obligation. Further background on the Trust is provided in Exhibit A.

Reporting Period Activity

Extension of the Other Opioid Claims Objection Deadline

During the Period MDT II continued to engage with those entities having filed Other Opioid Claims to resolve these claims as efficiently as possible. At this time, it is not anticipated that any of these claims will have a material impact on the assets of the Trust. The current objection deadline for Other Opioid Claims is the later of: (a) March

¹ Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Chapter 11 Plan confirmed in the bankruptcy cases of Mallinckrodt plc, *In re Mallinckrodt plc*, Case No. 20-12522 (Bankr. D. Del.) (the “Plan”).

² MDT II’s prior reports are available on both the *In re Mallinckrodt* docket and the MDT II website (<https://www.opioidmasterdisbursementtrust.com/Mallinckrodt/PeriodicReports>).

Opioid Master Disbursement Trust II

13, 2025, or (b) one hundred twenty (120) days following the date that a proof of Other Opioid Claim is amended in writing by or on behalf of a holder of such Other Opioid Claim.

Financial Update

During the Period, the Trust began with a cash balance of \$127,604,808, received \$2,407,949 of interest and other income (~4.95% annualized rate on interest income) and disbursed \$4,199,049, comprised entirely of Trust expenses, resulting in a \$125,813,708 ending Trust cash balance.

The Trust's ending cash balance was \$125,813,708, comprised of the Operating Reserve (\$100,998,137) and the amounts set aside (and still held) for the Municipal and Tribe Opioid Attorneys' Fee Fund (\$24,815,571). At this time, all assets are held in short term U.S. Government obligations.

Legal Matters Update

Under the Plan, the Trust was assigned certain claims against third parties. The claims being pursued are described in greater detail below.

1. Insurance Action (*Opioid Master Disbursement Trust II a/k/a Opioid MDT II v. Ace American Insurance Company, et al.*, Case No. 22SL-CC02974 (Mo. Cir. Ct.))

On June 16, 2022, the Trust filed a lawsuit in St. Louis County, Missouri against insurers that had issued certain policies under which rights were transferred to the Trust pursuant to the Plan, seeking insurance coverage with respect to the opioid-related claims that were channeled to the Trust and Opioid Creditor Trusts under the Plan. On December 20, 2023, the Trust filed a separate but related lawsuit involving certain additional insurance policies that it discovered through a third-party subpoena. Upon the Trust's motion, these two lawsuits were consolidated on January 30, 2024. By final order dated March 5, 2024, certain insurance policies were dismissed with prejudice due to a forum-selection clause in or incorporated in those policies that the insurers

Opioid Master Disbursement Trust II

contend mandates exclusive jurisdiction over any coverage disputes in the courts of England or Wales.

On April 16, 2024, the Trust filed a motion for partial summary judgment regarding exclusions in certain policies for bodily injury included within the so-called products hazard. The Trust contends that these products-hazard exclusions do not apply to bodily injury arising in whole or in part from opioid pharmaceuticals not manufactured or sold by Mallinckrodt, or from illicit opioid drugs. On July 17, 2024, the insurers filed cross motions, arguing that the exclusions eliminate coverage under many of the policies at issue in the case. The court heard argument on January 31, 2025, and has taken the motions under advisement.

The court issued a limited stay of discovery pending resolution of the products-hazard exclusion issue. Pursuant to the stay order, fact discovery will continue for at least ten months after determination of the motions. While the motions are under consideration, the parties will continue to address existing document discovery and may bring any discovery disputes arising out of the parties' pending discovery to the Court while the balance of discovery is deferred. The parties may also propound discovery requests on third parties during the pendency of the motions.

The next case management conference will be scheduled following the court's decision on the motion and cross motions for partial summary judgment.

2. Covidien Spinoff Action (*Opioid Master Disbursement Trust II v. Covidien Unlimited Co., et al.*, Adv. Pro. No. 22-50433 (Bankr. D. Del.))

On October 11, 2022, the Trust commenced an adversary proceeding in the U.S. Bankruptcy Court for the District of Delaware against Covidien Unlimited Company, Mallinckrodt's former parent, and three of its subsidiaries, hereinafter referred to, collectively, as "Covidien." On January 18, 2024, the Trust won a key opening victory, surviving Covidien's motion to dismiss. The Court allowed the majority of the Trust's claims, namely for intentional fraudulent transfer, reimbursement, indemnification, contribution, equitable subordination, and disallowance pursuant to Sections 502(d) and

Opioid Master Disbursement Trust II

502(e) of the Bankruptcy Code, to proceed. The Court dismissed the claims for constructive fraudulent transfer, breach of fiduciary duty as a promoter, and equitable disallowance. The Court also granted the motion to amend with respect to the claims that it allowed to proceed. Covidien filed its answer on March 25, 2024.

Through the surviving claims, the Trust seeks to avoid and recover (a) the value of the entire Covidien enterprise (without the Mallinckrodt business) at the time of the 2013 spinoff of Mallinckrodt from Covidien; (b) approximately \$867 million in net cash transfers that Mallinckrodt paid to Covidien from 2010 through 2012; and (c) approximately \$721 million in Mallinckrodt note proceeds that Covidien received before completing the spinoff. In addition, the Trust seeks to avoid (i) the putative indemnification obligations that Covidien imposed on Mallinckrodt under the spinoff agreement and (ii) certain pre-spin tax liabilities in the hundreds of millions of dollars that Covidien imposed on Mallinckrodt in connection with the spinoff, and to recover from Covidien (iii) the value of any payments that Mallinckrodt made on account of those pre-spinoff tax liabilities. The Trust also has a claim for reimbursement, indemnification, and contribution for the opioid-related costs incurred by Mallinckrodt.

The litigation is now in the discovery phase. Fact discovery is to be completed by April 30, 2025. The Court allowed Covidien to file an initial summary judgment motion limited to 11 U.S.C. § 546(e) issues. Briefing on that motion was completed on January 31, 2025.

3. Share Repurchase Program Action (*Opioid Master Disbursement Trust II v. Argos Capital Appreciation Master Fund LP, et al.*, Adv. Pro. No. 22-50435 (Bankr. D. Del.))

On October 12, 2022, the Trust commenced an adversary proceeding in the U.S. Bankruptcy Court for the District of Delaware against 72 defendant participants in Mallinckrodt plc's share repurchase program (the "SRP"). On October 24, 2023, the Trust amended its complaint to add 43 additional Defendants that were identified during the Trust's investigation. To date, the Trust has also voluntarily dismissed 40 Defendants.

The Trust asserts causes of action for intentional and constructive fraudulent transfers

Opioid Master Disbursement Trust II

through which it seeks to avoid and recover some of the over \$1 billion in cash transfers Mallinckrodt plc paid to its equity owners through the SRP between 2015 and 2018. The Trust asserts that the shares Mallinckrodt purchased through the SRP were worthless because Mallinckrodt was deeply insolvent at the time of the repurchases due to massive liabilities incurred from the manufacture, promotion, and distribution of opioid products. The Trust asserts that the cash paid to Mallinckrodt shareholders through the SRP was wrongly diverted and should be recouped for the benefit of Mallinckrodt's creditors.

On May 15, 2023, the Court approved a protocol whereby Defendants may assert individual affirmative defenses to the claims alleged in the SRP action, including that a given Defendant is protected by the safe-harbor provisions of 11 U.S.C. § 546(e) or received the proceeds of share repurchase transactions as a mere conduit. The Trust has been responding to Defendants who have asserted defenses under the protocol. To date, Defendants have filed eight motions to dismiss or for summary judgment pursuant to the protocol with the Court. The Court heard arguments on four of the motions on May 14, 2024.

On September 5, 2024, the Court granted summary judgment for defendants on the four motions on the grounds that the Trust's claims were barred by § 546(e) and that certain defendants were not transferees of the share repurchases. On September 19, 2024, the Trust filed with the District Court a notice of appeal and motion for leave to pursue an interlocutory appeal from the Bankruptcy Court's decision on the issue of whether Mallinckrodt's share repurchases could be protected from avoidance under § 546(e) when they were void *ab initio* under applicable nonbankruptcy law. Thereafter, the parties asked the Bankruptcy Court to issue a final judgment as to these four motions so that the Trust would have an appeal of right from the Bankruptcy Court's decision, which would render the Trust's motion for leave to pursue an interlocutory appeal moot. The Bankruptcy Court issued the final judgment on January 13, 2025. On January 23, 2025, the Trust filed an amended notice of appeal, and on January 28, 2025, the District Court denied the Trust's motion for leave to pursue an interlocutory appeal as moot. The Trust's appeal therefore remains pending. The Trust filed its designation of the record and statement of the issue presented on appeal on February 6, 2025.

Opioid Master Disbursement Trust II

On October 31, 2024, the parties completed briefing on three additional motions to dismiss filed under the protocol and are awaiting the Bankruptcy Court's decision. Briefing on an additional motion for summary judgment that was filed under the protocol will be completed on February 7, 2025. The Trust has also settled with [twelve] defendants for monetary consideration.

Opioid Master Disbursement Trust II

Exhibit A

Opioid Master Disbursement Trust II Background

The Opioid Master Disbursement Trust II was established pursuant to the chapter 11 Plan confirmed in the bankruptcy cases of Mallinckrodt plc, *In re Mallinckrodt plc*, Case No. 20-12522 (Bankr. D. Del.), confirmed by order dated March 2, 2022, and effective as of June 16, 2022 (the “2022 Plan”).

Pursuant to the 2022 Plan, MDT II was formed as a “hub” trust in a “hub & spoke” trust design, created to receive distributions (from funds paid by Mallinckrodt and any litigation recoveries) and then make distributions to the “spoke” beneficiary trusts: the Public Creditor Trusts (for the U.S. States and Territories and local governments within U.S. States and Territories, as well as the federally-recognized American Indian and Alaska Native Tribes) and the Private Creditor Trusts (for, e.g., personal injury victims, persons afflicted by neonatal abstinence syndrome, hospitals).

In the spring of 2023, following the rapidly deteriorating financial condition of Mallinckrodt and an aggressive letter-writing campaign by various stakeholders of the company, the MDT II Trustees determined that it was in the best interests of MDT II’s beneficiaries to engage in conversations with the company to restructure the remaining Opioid Deferred Cash Payments (which at the time totaled \$1.275 billion, and included the \$200 million payment that was due on June 16, 2023). Without a comprehensive deal, MDT II’s status as an unsecured creditor in a free fall bankruptcy would have left the trust subordinate to approximately \$3.5 billion in secured debt. Following weeks of intensive negotiations, MDT II, along with other key stakeholders, signed a restructuring support agreement (the “2023 RSA”) with the company on August 23, 2023, setting forth the terms of a prepackaged financial restructuring plan.

On August 28, 2023, Mallinckrodt commenced bankruptcy proceedings (see *In re Mallinckrodt plc*, Case No. 20-12522 (Bankr. D. Del.)), on October 10, 2023, its second Plan of Reorganization was confirmed, and on November 14, 2023, its second Plan of Reorganization went effective (the “2023 Plan”).

Pursuant to the 2023 RSA and 2023 Plan, MDT II received a one-time payment of \$250

Opioid Master Disbursement Trust II

million in full satisfaction of the remaining Opioid Deferred Cash Payments, and disbursed the full amount to the Public and Private Opioid Creditor Trusts, per the waterfall under the 2022 Plan, on August 29, 2023. MDT II also received enhanced cooperation under the Cooperation Agreement to facilitate the prosecution of the three MDT II third-party litigations (reducing costs for the Trust), and contingent value rights (“CVR”), essentially warrants, in the company (which will provide some value if the performance of the company dramatically improves).

The MDT II’s primary responsibilities are to: (i) receive the opioid settlement funds from Mallinckrodt (an obligation amended pursuant to the 2023 RSA and 2023 Plan); (ii) investigate and pursue claims against third parties that are assigned to the MDT II; (iii) fix a bar date and administer Other Opioid Claims that were not resolved as part of the Plan (a process that is still on-going); and (iv) make distributions to the Public and Private Creditor Trusts per the allocations in the Plan. These Opioid Creditor Trusts disburse funds received from MDT II to their respective creditors to be used for approved opioid abatement strategies or, in the case of the PI Trust, to compensate individuals for damages because of opioid-related bodily injuries.

More information about the Trust, including important documents, biographies of the MDT II Trustees (Jenni Peacock, Michael Atkinson, and Anne Ferazzi), and answers to frequently asked questions, can be found on the Trust’s website: <https://www.opioidmasterdisbursementtrust.com/Mallinckrodt>.

Opioid Master Disbursement Trust II

Appendix³

³ Note: Figures herein reflect Trust activity subsequent to the receipt and disbursement of the Initial Opioid Deferred Cash Payment where applicable. Expenses exclude fees incurred during the Period but unpaid as of January 31, 2025.

Opioid Master Disbursement Trust II

Appendix 1: Trust Financial Summary

Trust Activity Summary for Eighth Reporting Period (October 1, 2024 – January 31, 2025):

(\$ in actuals)	Beginning Balance	MDT II Period Receipts			MDT II Period Disbursements			Ending Balance
		Opioid Deferred Cash Payments	Interest and Other Income	Total Receipts	Distributions	Expenses (Litigation & Administrative)	Total Disbursements	
Operating Reserve	\$103,164,970	-	\$2,032,215	\$2,032,215	-	(\$4,199,049)	(\$4,199,049)	\$100,998,137
Third-Party Payor Reserve	-	-	-	-	-	-	-	-
Municipal and Tribe Opioid Attorneys' Fee Fund	24,439,838	-	375,734	375,734	-	-	-	24,815,571
Ratepayer Account	-	-	-	-	-	-	-	-
Opioid MDT II Total	\$127,604,808	-	\$2,407,949	\$2,407,949	-	(\$4,199,049)	(\$4,199,049)	\$125,813,708

Trust Activity Cumulative Summary (June 1, 2022 – January 31, 2025):

(\$ in actuals)	Beginning Balance	MDT II Cumulative Receipts			MDT II Cumulative Disbursements			Ending Balance
		Opioid Deferred Cash Payments	Interest and Other Income	Total Receipts	Distributions	Expenses (Litigation & Administrative)	Total Disbursements	
Operating Reserve ⁽¹⁾	\$134,953,403	-	\$17,744,138	\$17,744,138	-	(\$51,699,404)	(\$51,699,404)	\$100,998,137
Third-Party Payor Reserve	29,363,667	-	-	-	(29,363,667)	-	(29,363,667)	-
Municipal and Tribe Opioid Attorneys' Fee Fund	11,276,655	11,303,789	2,235,127	13,538,917	-	-	-	24,815,571
Ratepayer Account	3,000,000	-	-	-	(3,000,000)	-	(3,000,000)	-
Opioid MDT II Total	\$178,593,724	\$11,303,789	\$19,979,265	\$31,283,055	(\$32,363,667)	(\$51,699,404)	(\$84,063,071)	\$125,813,708

Opioid Master Disbursement Trust II

Trust Operating Reserve Additional Detail:

(\$ in actuals)

	Actual	Actual
	Jun 24 – Sep 24 <i>(4 months)</i>	Oct 24 - Jan 25 <i>(4 months)</i>
Beginning Cash	\$105,775,046	\$103,164,970
Professional Fees - Legal & Litigation Support	(\$4,099,956)	(\$3,721,216)
Trustee Fees & Expenses	(258,333)	(258,333)
Professional Fees - Financial & Tax	(100,000)	(125,000)
Insurance	(182,935)	-
Other	(68,967)	(94,500)
Total Trust Expenses	(\$4,710,191)	(\$4,199,049)
Interest and Other Income	2,100,115	2,032,215
Ending Cash	\$103,164,970	\$100,998,137

Memo: Trust Operating Reserve Detail

Total Fees: Litigation	4,017,450	3,721,179
Total Fees: Administrative	692,741	477,870
Total Fees	\$4,710,191	\$4,199,049

Opioid Master Disbursement Trust II

Appendix 2: Trust Budget

Pursuant to the 2022 Plan, Mallinckrodt was obligated to make 9 cash payments over 8 years on account of the Opioid Deferred Cash Payments. The scheduled payments totaled \$1,725,000,000, of which ~\$1,718,000,000 was to be paid to the Trust. However, given the Company's financial performance, an agreement was reached between the Company, its financial creditors and the Trust to settle all remaining Opioid Deferred Cash Payments for a final payment prior to its 2023 Chapter 11 filing. The Trust received a second and final payment of \$250,000,000 on August 24, 2023, which it then distributed to the opioid creditor trusts per the 2022 Plan.¹ The Trust may receive additional amounts on account of assigned litigation claims and interest income, but none of these amounts are certain nor can they be estimated at this time.

In the third year of its operations, the Trust is projected to disburse \$16,758,388 on account of its expenses (i.e., excluding disbursements to creditor trusts) comprised of \$15,167,838 for legal and litigation support, \$775,000 for trustee fees and expenses, \$341,782 for financial and tax advisory services, \$182,935 for insurance, and \$290,833 for other expenses.

¹ The Trust also received enhanced cooperation under the Cooperation Agreement to facilitate the prosecution of the three MDT II third-party litigations (reducing costs for the Trust) and contingent value rights ("CVR"), essentially warrants, in the company (which will provide some value if the value of the company dramatically improves from levels at emergence).

Opioid Master Disbursement Trust II

Trust Period Expense and Operating Budget:

Appendix 2: Trust Forecast

(\$ in actuals)

	Actual	Actual	Forecast	Total
	Jun 24 - Sep 24 (4 months)	Oct 24 - Jan 25 (4 months)	Feb 25 - May 25 (4 months)	Jun 24 - May 25 (12 months)
Beginning Cash	\$105,775,046	\$103,164,970	\$100,998,137	\$105,775,046
Professional Fees - Legal & Litigation Support	(\$4,099,956)	(\$3,721,216)	(\$7,346,667)	(\$15,167,838)
Trustee Fees & Expenses	(258,333)	(258,333)	(258,333)	(775,000)
Professional Fees - Financial & Tax	(100,000)	(125,000)	(116,782)	(341,782)
Insurance	(182,935)	-	-	(182,935)
Other	(68,967)	(94,500)	(127,367)	(290,833)
Total Trust Expenses	(\$4,710,191)	(\$4,199,049)	(\$7,849,148)	(\$16,758,388)
Interest and Other Income	2,100,115	2,032,215	1,572,087	5,704,418
Ending Cash	\$103,164,970	\$100,998,137	\$94,721,075	\$94,721,075